RxDoctor Payments Data

Annie Morrissey, MD

Endocrinology, Diabetes & Metabolism · Fayetteville, GANPI 1558527127

Payments from drug & device makers

$3,741in general payments, 2019–2025

Across 179 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$471
  • Lilly USA, LLC$381
  • Sanofi-aventis U.S. LLC$352
  • Amgen$269
  • Abbott$267
  • Corcept Therapeutics$201
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,62897%
  • Education$541%
  • Gifts$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,741 in reported general payments places this provider in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$130,239
Medicare patients
441
Services billed
2,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide361$623,872
MounjaroTirzepatide170$280,853
JardianceEmpagliflozin210$242,818
TrulicityDulaglutide114$171,001
Tresiba Flextouch U-100Insulin Degludec175$127,651
FarxigaDapagliflozin Propanediol91$124,060
JanuviaSitagliptin Phosphate102$121,334
Tresiba Flextouch U-200Insulin Degludec57$84,473
RybelsusSemaglutide36$64,182
ProliaDenosumab27$46,807
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog85$42,420
Humalog Kwikpen U-100Insulin Lispro97$39,115
Novolog FlexpenInsulin Aspart103$29,150
Lantus SolostarInsulin Glargine,hum.Rec.Anlog140$25,420
Soliqua 100-33Insulin Glargine/Lixisenatide15$23,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$471$696,340432 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$381$460,243313 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$200$282,455256 claims
MerckJanuvia, Janumet Xr$38$141,892130 claims
AstraZenecaFarxiga$113$124,06091 claims
AmgenProlia$269$46,80727 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$352$29,15444 claims
AbbVieSynthroid$156$18,486190 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$64$6,675586 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →